Bio company Embrix (CEO Sang-won Jeong) announced that it has received a formal registration decision from the United States Patent and Trademark Office (USPTO) for its self-developed gene therapy delivery platform, 'Navibody.'
The Navibody platform utilizes a technology that self-assembles antibodies onto the surface of mRNA-encapsulated lipid nanoparticles (LNPs), enabling the selective delivery of genetic material to specific target cells. When applied with T-cell-targeting antibodies, it delivers mRNA containing the CAR gene to T cells, enabling the in vivo CAR-T cell therapy, which directly forms CAR-T cells within the body.
Embrix is developing MIC-001, an in vivo CAR-T pipeline based on this platform. The company has completed proof-of-concept by confirming T-cell-specific CAR gene expression and anticancer efficacy in nonclinical trials using human perfused bone marrow cells (hPBMCs). Research is currently underway, aiming to secure safety and efficacy data in nonhuman primates (NHPs) or comparable higher-order animal models.
The company plans to verify the reproducibility and scalability of its Navibody-based in vivo CAR-T platform through future in vivo data and expand the scope of clinical applications, including repeat administration and combination therapy strategies.
Meanwhile, Embrix participated in BIO-Europe 2025, held in Vienna, Austria in November 2025, and discussed its in vivo CAR-T pipeline centered around MIC-001 with global pharmaceutical and bio companies. It is reported that it has currently signed or is in negotiations with multiple companies for Material Transfer Agreements (MTAs) and Non-Disclosure Agreements (CDAs).
- See more related articles
You must be logged in to post a comment.